American Journal Of Drug And Alcohol Abuse

雜志介紹

American Journal Of Drug And Alcohol Abuse雜志介紹

《American Journal Of Drug And Alcohol Abuse》是一本以English為主的未開放獲取國際優秀期刊，中文名稱美國藥物和酒精濫用雜志，本刊主要出版、報道醫學-PSYCHOLOGY, CLINICAL領域的研究動態以及在該領域取得的各方面的經驗和科研成果，介紹該領域有關本專業的最新進展，探討行業發展的思路和方法，以促進學術信息交流，提高行業發展。該刊已被國際權威數據庫SCIE、SSCI收錄，為該領域相關學科的發展起到了良好的推動作用，也得到了本專業人員的廣泛認可。該刊最新影響因子為2.7，最新CiteScore 指數為4.7。

本刊近期中國學者發表的論文主要有：

• Effects of ketamine use on psychotic disorders and symptoms in male, methamphetamine-dependent subjects.

  Author: Dong H^1,2, Yang C², Shen Y², Liu L³, Liu M², Hao W².

• Nonconformist tendencies related to risky choices in female methamphetamine abstainers.

  Author: Wei S^1,2, Liu Q^3,4, Harrington M⁴, Sun J⁵, Yu H^2,6, Han J⁷, Hao M⁷, Wu H^2,8,9, Liu X^2,8.

• The association of HTR3A mRNA expression and craving in Han Chinese alcohol-dependent patients: a preliminary study.

  Author: Xu YH, Wang LL, Shi L, Lei JP, Miao Q, Liu TQ, Hao W, Lu L, Zhang RL.

• Ethanol alters the expression of ion channel genes in Daphnia pulex.

  Author: Hu AM, Zhu T, Dong L, Luo NF, Du GZ.

英文介紹

American Journal Of Drug And Alcohol Abuse雜志英文介紹

The American Journal of Drug and Alcohol Abuse (AJDAA) is an international journal published six times per year and provides an important and stimulating venue for the exchange of ideas between the researchers working in diverse areas, including public policy, epidemiology, neurobiology, and the treatment of addictive disorders. AJDAA includes a wide range of translational research, covering preclinical and clinical aspects of the field. AJDAA covers these topics with focused data presentations and authoritative reviews of timely developments in our field. Manuscripts exploring addictions other than substance use disorders are encouraged. Reviews and Perspectives of emerging fields are given priority consideration.

Areas of particular interest include: public health policy; novel research methodologies; human and animal pharmacology; human translational studies, including neuroimaging; pharmacological and behavioral treatments; new modalities of care; molecular and family genetic studies; medicinal use of substances traditionally considered substances of abuse.